Measures activity, not value. Not investment advice.
Institutional holders rose 13% to 346 while the stock is up 21% in a year.
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
No income statement in this company's recent SEC filings in our data (it may report under IFRS, in another currency, or not file with the SEC).
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$6.2M
bought $0, sold $6.2M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+13%
346 13F filers vs 307
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
68.3M shares held by 13F filers (30 Sep 2026) of 62.0M outstanding (31 Dec 2025); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
4.8%
3.0M shares sold short (30 Oct 2026) of 62.0M outstanding (31 Dec 2025)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.0
3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-4.3%
3.1M shares sold short in the report before, 3.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
53%
53% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$30.1
the 12 months before: $210K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$760K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
24
24 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
12×
24 articles in the last 7 days; its usual week has 2.
Price $252.73 on 20 Nov 2026, +21% over 12 months (12-month range $196.63 to $277.18)
Sharp change
Lobbying filing
Insider net buying (open market). Insiders sold a net $10.0M in the last 12 months (the 12 months before: $0).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).Institutional holders (13F filers). 346 13F filers reported holding it in the latest 13F quarter, +29% on a year earlier.Federal obligations. Federal obligations: $30.1 published in the last 12 months, -100% on the 12 months before.Lobbying spend. Lobbying spend: $760K published in the last 12 months, +31% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, capital spending per quarter, workers in warn layoff notices.
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $5.3M (18 Nov 2026), higher than 100% of its own history.
Reported lobbying spend: $170K in Q3 2026, $170K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
reported $280K of lobbying spend for the quarter ended 31 Mar 2024, 1.3× the same quarter last year.
Same quarter last year: $210K; its normal quarter is $130K.
See the evidence
This period
$280K (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$130K
Typical spread (median absolute deviation)
$10K
How far from its usual level
+7.5
Same quarter last year
$210K
History used
1,370 days
the quarter ended 31 Mar 20248 earlier quartersnormal: $130K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
saw 35 13F filers open a new position in the quarter ended 30 Sep 2022, 1.5× the same quarter last year.
Same quarter last year: 23; its normal quarter is 20.5.
See the evidence
This period
35 (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
20.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.8
Same quarter last year
23
History used
2,740 days
the quarter ended 30 Sep 20228 earlier quartersnormal: 20.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 6.9M shares sold short in the 15 Jul 2022 report, 2.6× the same report last year.
Same report last year: 2.7M; its normal report is 2.8M.
See the evidence
This period
6.9M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
454K
How far from its usual level
+6.0
Same report last year
2.7M
History used
1,659 days
the 15 Jul 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.5M shares sold short in the 30 Jun 2022 report, 2.4× the same report last year.
Same report last year: 2.7M; its normal report is 2.8M.
See the evidence
This period
6.5M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
391K
How far from its usual level
+6.4
Same report last year
2.7M
History used
1,644 days
the 30 Jun 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.9M shares sold short in the 15 Jun 2022 report, 2.1× the same report last year.
Same report last year: 2.8M; its normal report is 2.8M.
See the evidence
This period
5.9M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
373K
How far from its usual level
+5.7
Same report last year
2.8M
History used
1,629 days
the 15 Jun 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.4M shares sold short in the 31 May 2022 report, 2.1× the same report last year.
Same report last year: 3.0M; its normal report is 2.8M.
See the evidence
This period
6.4M (the 31 May 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
349K
How far from its usual level
+6.9
Same report last year
3.0M
History used
1,614 days
the 31 May 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.7M shares sold short in the 13 May 2022 report, 2.3× the same report last year.
Same report last year: 3.0M; its normal report is 2.8M.
See the evidence
This period
6.7M (the 13 May 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
287K
How far from its usual level
+9.3
Same report last year
3.0M
History used
1,596 days
the 13 May 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.8M shares sold short in the 29 Apr 2022 report, 1.9× the same report last year.
Same report last year: 3.0M; its normal report is 2.8M.
See the evidence
This period
5.8M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
221K
How far from its usual level
+9.0
Same report last year
3.0M
History used
1,582 days
the 29 Apr 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.3M shares sold short in the 14 Apr 2022 report, 2.1× the same report last year.
Same report last year: 3.0M; its normal report is 2.8M.
See the evidence
This period
6.3M (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
203K
How far from its usual level
+11.6
Same report last year
3.0M
History used
1,567 days
the 14 Apr 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.3M shares sold short in the 31 Mar 2022 report, 2.2× the same report last year.
Same report last year: 2.9M; its normal report is 2.8M.
See the evidence
This period
6.3M (the 31 Mar 2022 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
199K
How far from its usual level
+11.9
Same report last year
2.9M
History used
1,553 days
the 31 Mar 2022 report24 earlier reportsnormal: 2.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.6M shares sold short in the 15 Mar 2022 report, 1.6× the same report last year.
Same report last year: 2.9M; its normal report is 2.7M.
See the evidence
This period
4.6M (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
251K
How far from its usual level
+4.9
Same report last year
2.9M
History used
1,537 days
the 15 Mar 2022 report24 earlier reportsnormal: 2.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 14 May 2021 report, 1.5× the same report last year.
Same report last year: 2.0M; its normal report is 2.1M.
See the evidence
This period
3.0M (the 14 May 2021 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
142K
How far from its usual level
+4.5
Same report last year
2.0M
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 30 Apr 2021 report, 1.6× the same report last year.
Same report last year: 1.9M; its normal report is 2.0M.
See the evidence
This period
3.0M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
124K
How far from its usual level
+4.8
Same report last year
1.9M
History used
1,218 days
the 30 Apr 2021 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 15 Apr 2021 report, 1.5× the same report last year.
Same report last year: 2.1M; its normal report is 2.0M.
See the evidence
This period
3.0M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
122K
How far from its usual level
+4.8
Same report last year
2.1M
History used
1,203 days
the 15 Apr 2021 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.9M shares sold short in the 31 Mar 2021 report, 1.5× the same report last year.
Same report last year: 2.0M; its normal report is 2.0M.
See the evidence
This period
2.9M (the 31 Mar 2021 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
108K
How far from its usual level
+4.5
Same report last year
2.0M
History used
1,188 days
the 31 Mar 2021 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.9M shares sold short in the 15 Mar 2021 report, 1.4× the same report last year.
Same report last year: 2.1M; its normal report is 2.0M.
See the evidence
This period
2.9M (the 15 Mar 2021 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
105K
How far from its usual level
+4.2
Same report last year
2.1M
History used
1,172 days
the 15 Mar 2021 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.6M shares sold short in the 15 Apr 2019 report, 7.1× the same report last year.
Same report last year: 226K; its normal report is 385K.
See the evidence
This period
1.6M (the 15 Apr 2019 report)
Normal report (median of 24 earlier)
385K
Typical spread (median absolute deviation)
161K
How far from its usual level
+5.1
Same report last year
226K
History used
472 days
the 15 Apr 2019 report24 earlier reportsnormal: 385K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 29 Mar 2019 report, 2.6× the same report last year.
Same report last year: 550K; its normal report is 385K.
See the evidence
This period
1.4M (the 29 Mar 2019 report)
Normal report (median of 24 earlier)
385K
Typical spread (median absolute deviation)
161K
How far from its usual level
+4.3
Same report last year
550K
History used
455 days
the 29 Mar 2019 report24 earlier reportsnormal: 385K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 15 Mar 2019 report, 2.1× the same report last year.
Same report last year: 628K; its normal report is 385K.
See the evidence
This period
1.4M (the 15 Mar 2019 report)
Normal report (median of 24 earlier)
385K
Typical spread (median absolute deviation)
161K
How far from its usual level
+4.0
Same report last year
628K
History used
441 days
the 15 Mar 2019 report24 earlier reportsnormal: 385K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Not listed: 15 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001612042
Ticker
ASND
Domain
ascendispharma.com
Employer name
Ascendis Pharma Inc. (1 unverified)
Lobbying client
ascendis pharma
Name
Ascendis Pharma A/S Ordinary Share
Uei
KV6MU52GJMF5, T2AMZHL9TMM4, UKN2MTNJ9WM5
Wikidata
Q104479983
DOL H-1B labor condition applications and PERM certifications86 data points24 Aug 2020 to 3 Aug 2026
Federal lobbying disclosures (LDA)3 records, 78 data points27 May 2020 to 30 Sep 2026
SEC Form 13F institutional holdings423 data points31 Mar 2015 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)11 records15 Apr 2016 to 11 Feb 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)9 data points31 Dec 2017 to 31 Dec 2025
SEC Form 4 insider transactions9 records, 32 data points12 May 2026 to 18 Nov 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards6 data points15 Jul 2025 to 4 Feb 2026